CD46 is used by human group B adenoviruses (Ads) as a high-affinity attachment receptor. Here we show evidence that several group B Ads utilize an additional receptor for infection of human cells, which is different from CD46. We tentatively named this receptor receptor X. Competition studies with unlabeled and labeled Ads, recombinant Ad fiber knobs, and soluble CD46 and CD46 antibodies revealed three different subgroups of group B Ads, in terms of their receptor usage. Group I (Ad16, -21, -35, and -50) nearly exclusively uses CD46. Group II (Ad3, -7p, and -14) utilizes receptor X and not CD46. Group III (Ad11p) uses both CD46 and the alternative receptor X. Interaction of group II and III Ads with receptor X occurs via the fiber knob. Receptor X is an abundantly expressed glycoprotein that interacts with group II and III Ads at relatively low affinity in a Ca 2؉ -dependent manner. This receptor is expressed at high levels on human mesenchymal and undifferentiated embryonic stem cells, as well as on human cancer cell lines. These findings have practical implications for stem cell and gene therapy.
cultured in medium containing serum replacer (Invitrogen) on gamma-irradiated primary mouse embryonic fibroblasts. Cultures were passaged with dispase. Cells were passaged 1 day prior to being exposed to virus. They were either plated onto feeders in unconditioned medium or onto Matrigel (Becton Dickinson, Franklin Lakes, NJ)-coated plates in filtered (0.22-m-pore-size filter) human ES cell medium that had been conditioned by unirradiated mouse embryonic fibroblasts for 24 h.
Viruses. Ad3 (GB strain), Ad7p (Gomen strain), Ad11p (Slobitzki strain), Ad14 (DeWit strain), Ad16 (Ch.79 strain), Ad21 (AV-1645 strain), Ad35 (Holden strain), and Ad50 (Wan strain) were all obtained from the American Type Culture Collection. Chimeric Ads, based on serotype 5 but possessing the fiber shaft and knob domains of serotype 35 (Ad5/35) or serotype 11 (Ad5/11), were previously constructed and express green fluorescent protein (GFP) as a transgene under the control of the cytomegalovirus (CMV) promoter (Ad5/35-CMV-GFP, Ad5/11-CMV-GFP) (35, 40) or express the Escherichia coli lacZ gene under the control of the Rous sarcoma virus (RSV) promoter (Ad5/35-RSV-␤-Gal, Ad5/11-RSV-␤-Gal) (25) . The Ad5/3-CMV-GFP vector was generously provided by David Curiel (University of Alabama at Birmingham). Ads were propagated in 293 cells, methyl-3 H thymidine labeled, and purified, and titers of genomes and viral particles (VP) and PFU were determined as described elsewhere (35) . Ad3 and Ad35 were labeled with Cy3 by using Fluorolink Cy3 reactive dye according to the manufacturer's (Amersham, Little Chalfont, Buckinghamshire, United Kingdom) instructions.
Antibodies, recombinant fiber knobs, soluble CD46, and siRNA. Monoclonal antibodies (MAbs) directed against the CD46 CCP1 domain (J4-48; Research Diagnostics), the CD46 CCP2 domain (MEM-258; Serotec), the CD46 CCP3/4 domain (GB-24) (8), integrin ␣2 (DX5; Immunotech), integrin ␣3 (P1B5; Gibco), integrin ␣4 (9F10; Pharmingen), integrin ␣5 (IIA1; Pharmingen), integrin ␣6 (GoH3; Pharmingen), integrin ␣v (L230; ATTC), integrin ␤1 (P4C10; Chemicon), integrin ␤3 (AB1932; Chemicon), integrin ␤4 (439-9B; Pharmingen), and integrin ␣v␤5 (P1F6; Chemicon) were used for flow cytometry and to compete Ad binding in attachment and/or cytopathic effect (CPE) studies. The final antibody concentration was 10 g/ml for CPE and attachment assays. Small interfering RNA (siRNA) oligonucleotides were obtained from QIAGEN. CD46 siRNA, control siRNA, and transfection of siRNA into HeLa cells were described previously (7) . Integrin siRNAs were directed against the following sequences: integrin ␣v, 5Ј-AGCAACTTTATTATAGATTTA-3Ј; integrin ␤1, catalog no. SI00300573, target sequence not provided. Ad3, Ad11p, and Ad35 recombinant fiber knob domain proteins were prepared as described elsewhere (7) . The fiber knob proteins were dialyzed against 5 mM KCl, 17% glycerol, and 10 mM MgCl 2 . Soluble CD46 was prepared as described elsewhere (7) .
Flow cytometry. Adherent cells were detached by treatment with Versene (Gibco). After being washed, cells were resuspended in 120 l of wash buffer (WB; phosphate-buffered saline-1% fetal bovine serum) and incubated for 45 min at 4°C with MAbs (final concentration, 5 g/ml). Subsequently, cells were washed with WB two times and incubated with Alexa Fluor 488 goat anti-mouse antibody (1/100 dilution; Molecular Probes) or with Alexa Fluor 488 goat anti-rat antibody (1/100 dilution; Molecular Probes) for 30 min at 4°C. After incubation with the secondary antibody, cells were washed two times with WB and 10 4 cells were analyzed in duplicate by flow cytometry.
␤-Galactosidase (␤-Gal) and alkaline phosphatase expression. Ad5/35-RSV-␤-Gal and Ad5/11-RSV-␤-Gal transduction was detected by X-Gal staining. Cells were fixed with a solution containing PBS, 0.5% glutaraldehyde, and 1 mM MgCl 2 for 20 min at room temperature (RT). Staining for ␤-Gal was performed with 5-bromo-4-chloro-3-indolyl-␤-D-galactopyranoside (X-Gal) (7) . Alkaline phosphatase expression in ES cells was detected as described elsewhere (3) .
Attachment assays. Unless otherwise indicated, cells were detached from culture dishes by incubation with Versene and washed with PBS (Gibco). A total of 10 5 cells/tube were resuspended in 100 l of ice-cold adhesion buffer (DMEM supplemented with 2 mM MgCl 2 , 1% FCS, and 20 mM HEPES) containing 3 H-labeled Ad at a multiplicity of infection (MOI) of 8,000 VP per cell. After 1 h of incubation at 4°C, cells were pelleted and washed twice with 0.5 ml of ice-cold PBS. After the last wash, the supernatant was removed and the cell-associated radioactivity was determined with a scintillation counter. The number of VP bound per cell was calculated by using the virion specific radioactivity and the number of cells. Competition assays included the following modifications from the protocol described above. (i) For knob competition, various concentrations (0.01 to 20 g/ml) of fiber knob in 50 l adhesion buffer were added and allowed to attach for 45 min at 4°C before 3 H-labeled Ad was added to a final volume of 100 l. (ii) For antibody competition, 10 g/ml of antibody in 50 l adhesion buffer was added and allowed to attach for 30 min at 4°C before 3 H-labeled Ad was added to a final volume of 100 l. (iii) For cross competition, a 2-to 100-fold excess of unlabeled Ad in 50 l adhesion buffer was added and allowed to attach for 1 h at 4°C before 3 H-labeled Ad was added to a final volume of 100 l. (iv) For C3b competition, various concentrations (0.01 to 25 g/ml) of human purified C3b fragment (Antigen Site, San Diego, CA) in 50 l adhesion buffer were incubated with cells for 30 min at room temperature before 3 H-labeled Ad was added to a final volume of 100 l. (v) For soluble CD46 competition, 3 H-labeled Ad was incubated at a total volume of 100 l CD46 supernatant (diluted 1:1 with adhesion buffer) at room temperature for 1 h before addition to cells. Assays of attachment to HeLa cells were also performed as described above after detachment of cells from culture dishes with 0.05% trypsin-0.5 mM EDTA solution for 15 min or after deglycosylation by incubation with tunicamycin (Sigma) at a concentration of 0.1 or 0.5 g/ml for 48 h as described previously (8) .
To analyze the affinity of binding of the different Ads to their receptor(s), different amounts of 3 H-labeled Ad particles ranging from 2,000 to 800,000 VP per cell were incubated with 10 5 cells in the presence and absence of CD46 blockade (with or without preincubation of cells with the MEM-258 MAb for 30 min on ice). Numbers of attached VP per cell were determined, and Scatchard plots were made. The binding affinities (K a )S of individual Ads were calculated on the basis of the slope with standard Excel software. The number of receptor sites was extrapolated from the intercept of the lines with the x axis.
Ad-Cy3 attachment studies. MES cells were detached from culture dishes by incubation with Versene (Gibco), and 1 ϫ 10 4 cells/chamber were plated on eight-well Tissue-Tek chamber slides (Nalge Nunc International) and incubated at 37°C overnight. The next day, cells were incubated with Ad3 or Ad35 labeled with Cy3 at an MOI of 8,000 VP/cell at 4°C for 45 min in 200 l adhesion buffer. hSF6 and CD34 ϩ cells were incubated in suspension with 8,000 VP/cell Cy-3 labeled Ad3 or Ad35 at 4°C for 45 min in 100 l adhesion buffer. Cells were then washed with PBS, fixed for 15 min with acetone-methanol at 4°C, washed two times with PBS, and air dried. Cytospins of hSF6 and CD34 ϩ cells onto glass slides were done, and cells were analyzed by fluorescence microscopy.
CPE assay. A total of 2 ϫ 10 5 HeLa cells per well of a 24-well plate were incubated for 30 min at 4°C with 300 l DMEM-10% FCS-glutamine-Pen-Strep containing 10 g/ml MEM-258 antibody (Serotec) or J4-48 (Research Diagnostics). Thereafter, 700 l DMEM-10% FCS-glutamine-Pen-Strep containing unlabeled Ad at an MOI of 100 PFU/cell was added and cells were incubated at 37°C. After 48 h, the cells were washed with PBS and fixed with 4% paraformaldehyde for 3 min at room temperature. Fixed cells were washed with PBS and incubated for 3 min in 1% crystal violet in 70% ethanol, followed by three rinses with water. Air-dried cells were photographed.
RESULTS
Binding of group B Ads in the presence of CD46 blocking antibodies. To assess the differential utilization of CD46 and the new receptor X, we performed attachment studies with 3 H-labeled group B Ads in the presence and absence of anti-CD46 antibodies on a series of transformed and primary human cell cultures. We used an anti-CD46 MAb against CCP2 (MEM-258) that has been previously shown to specifically block binding of and infection of Ad35 fiber-containing Ad vectors (6) . We performed studies with Ad3, -7p, -14, -11p, -35, -16, -21, and -50 on human tumor cell lines of different tissue origins on the basis of the speculation that the expression levels of receptor X might vary between cell lines. The following cell lines were used: HeLa (cervical carcinoma), K562 (erythroleukemia), Hep-2 (larynx carcinoma), SKOV3 (ovarian cancer), 293 (neuronal origin), and Huh7 (hepatoma). Because CD46 is upregulated on tumors (12, 17, 24, 42) and tumor cell lines are thought to express high levels of CD46 (1), which might complicate the study of alternative receptors, a second set of binding studies was performed with primary human cells. We focused on cell types for potential use in ex vivo gene therapy such as human stem cells, DC, and skin fibroblasts (MHF2). Stem cells used in this study included hematopoietic stem cells residing in CD34
ϩ cord blood-derived cells (CD34 ϩ ), MES cells, and ES cells (line hSF6). Our previous work (7, 34) and Scatchard blot analyses described in this study (see Fig. 4 . Differences in the attachment of a given serotype to different cell lines might be due to different cell sizes and CD46 densities. In group II, binding of Ad3, Ad7, and Ad14 was blocked by MEM-258 MAb less than 48%, indicating that these serotypes preferentially use receptor X. The impact of binding through receptor X was different for different cell lines (potentially as a result of different receptor levels). Interestingly, interaction of Ad3 (and Ad7 and Ad14; data not shown) with 293 cells was nearly independent of CD46. In group III, attachment of Ad11p was blocked by the MEM-258 MAb between 40 and 80%, indicating that this serotype uses both CD46 and receptor X. The outcome of studies of binding to primary cells was similar to that observed for transformed cell lines. For group I Ads such as Ad35, as in tumor cell lines, binding could be efficiently blocked by the MEM-258 MAb. Binding of group II Ads such as Ad3 was not decreased in the presence of the MEM-258 MAb. Group III Ad11p binding to primary cells was partially inhibited by the MEM-258 MAb. Our data on the usage of CD46 by group B Ads were corroborated by studies with CHO cells that do (CHO-C2) or do not (CHO-K1) express CD46 ( Fig. 1) . We found that significantly more Ad11p, -16, -21, -35, and -50 particles bound to CHO-C2 than to CHO-K1, while binding of Ad3, Ad7, and Ad14 was not significantly different between the two cell lines. These findings corroborate our data obtained with the MEM-258 MAb and show that Ad3, -7, and -14 binding is largely independent of CD46.
Level of Ad attachment to different cell lines. For group I Ads such as Ad35, overall, fewer particles bound to primary cells compared to tumor cell lines (Table 2) . Group II Ad3 bound more efficiently than group I and III Ads to ES cells. In contrast, binding of group I and III Ads to CD34 ϩ cells, DC, and MHF2 was more efficient than that of group II Ads. In agreement with a recent study (33), we found that Ad3 binds less to DC than does Ad11p or Ad35 (whose binding is most likely mediated by CD46). Importantly, compared to skin fibroblasts, six out of the seven tumor cell lines we investigated showed elevated binding levels of Ad3 (differences: HeLa, 5.7-fold; Huh7, 4.5-fold; K562, 3.1-fold; Hep2, 2.8-fold; SKOV3, 1.8-fold). This indicates that receptor X might be upregulated in tumor cells.
Transduction of tumor and stem cells by group B Ads in the presence of CD46 blocking antibodies. Although it is thought that the degree of attachment largely determines the tropism a Cells were preincubated with anti-CD46 antibody MEM-258 or control antibody.
3 H-labeled Ads were then added at an MOI of 8,000 VP per cell, and the number of VP bound per cell was determined after 1 h of incubation at 4°C as described in Materials and Methods. Cell types are grouped as transformed or tumor cell lines, primary stem cells, and primary normal cells. Shown is the percentage of inhibition of binding after preincubation with control versus CD46 antibody. All samples were analyzed in triplicate. Standard deviation was less than 10%. in the presence of MEM-258. Again, this shows that infection via the Ad35 fiber depends to a larger degree on CD46 than infection via the Ad11 fiber (particularly at higher MOIs), while infection via the Ad3 fiber knob is largely independent of CD46.
The efficient interaction of Ad3 with stem cells (see Table 2 ) was corroborated by studies with Cy-3-labeled particles (Fig.  2C) . While Cy3-Ad3 bound to human ES cells as efficiently as Cy3-Ad35, fewer Cy3-Ad3 than Cy3-Ad35 particles bound to CD34 ϩ cells and MES cells. To study the involvement of CD46 and receptor X in transduction of human stem cells, we infected MES and ES cells with Ad5/35 (which uses CD46), Ad5/3 (which uses receptor X), and Ad5/11 (which uses CD46 and receptor X) vectors in the absence and presence of CD46 blocking antibodies. In MES cells, the MEM-258 MAb significantly reduced Ad5/35-CMV-GFP infection, while Ad5/3 and Ad5/11 infection was not affected (Fig. 2D ). This indicates that Ad5/3 and Ad5/11 infection of MES cells can occur via an alternative receptor, in a CD46-independent manner, whereas Ad5/35 transduction of MES cells is predominantly CD46 dependent. The effect of MEM-258 on infection of hSF6 cells was similar (Fig. 2E) . While the number of transgene-expressing cells decreased more than 70% for Ad5/35 vector-infected cells in the presence of MEM-258, antibody preincubation reduced transduction of Ad5/11 vectors only 13%. Interestingly, when infected with Ad5/11 and Ad5/35.CMV-GFP (at an MOI of 250 PFU/cell), only cells in the periphery of hSF6 clones that had undergone differentiation expressed GFP (Fig. 2E, left  side) . Apparently, the CMV promoter was not active in undifferentiated ES cells. In contrast, Ad5/11 and Ad5/35 vectors that contained the lacZ gene under the control of the RSV promoter conferred efficient transgene expression at the same MOI used for the GFP-expressing vectors in all ES cell subsets, including undifferentiated ES cells (Fig. 2E, right side) . Undifferentiated ES cells can be identified by positive staining for alkaline phosphatase (Fig. 2F) .
Cross competition with Ads and fiber knobs. To further investigate the use of receptor X by group B Ads, we performed cross-competition studies with HeLa cells with and without the MEM-258 MAb. In these studies, we used an excess of unlabeled virus that allowed for Ն85% inhibition of the corresponding 3 H-labeled virus binding to HeLa cells in the absence of the MEM-258 MAb, as shown, for example, in Fig. 3A for Ad35. Table 3 shows that Ad3, Ad7p, Ad11p, and Ad14 cross compete for CD46-independent binding, while Ad35 does not block the binding of these serotypes.
Furthermore, we carried out competition studies with recombinant fiber knob domains on HeLa cells. Ad3, Ad35, and Ad11 fiber knob domains were used at concentrations that inhibited binding of the corresponding virus more than 90% (Fig. 3B) . Notably, in contrast to Ad11 and Ad35, not all recombinant Ad3 knob protein was present in trimeric form (Fig. 3C) , which might affect the affinity of interaction with receptor X and might explain why 10-fold more Ad3 knob than Ad35 knob was needed to achieve the same inhibition of binding of the parental Ad. Importantly, the fact that Ad3 knob blocks Ad3 binding indicates that interaction with receptor X is fiber knob mediated. Cross-competition studies with fiber knobs revealed that Ad3 knob inhibits Ad7p and Ad14 binding but does not significantly block Ad11p binding (Table 4 ). It was surprising that Ad3 knob was unable to compete with Ad11p binding, in contrast to Ad3 virus. Only when interaction of Ad11p with CD46 is blocked by MEM-258 MAb does Ad3 (10 g/ml). Ads were then added at an MOI of 100 PFU/cell (ϳ2,000 VP/cell). Forty-eight hours after infection, cells were washed with PBS, fixed with 4% paraformaldehyde, and stained with crystal violet as described in Materials and Methods. MAb, and subsequently recombinant fiber knob proteins of Ad3 (10 g/ml), Ad11p (1 g/ml), and Ad35 (1 g/ml) were added. Thereafter, 3 H-labeled Ad11p was added at an MOI of 8,000 VP per cell and attachment was analyzed. bind. inh., binding inhibition. a Cells were preincubated with MAb MEM-258 followed by a 100-fold excess of unlabeled Ad. Control cells were incubated with MAb MEM-258 only. Thereafter, 3 H-labeled Ads were added at an MOI of 8,000 VP per cell and the number of VP bound per cell was determined after 1 h of incubation at 4°C. Percentage of binding inhibition compared to control settings was calculated. All samples were analyzed in triplicate. Standard deviation was less than 10%. a HeLa cells were preincubated with recombinant fiber knob proteins from Ad3 (10 g/ml), Ad11p (1 g/ml), or Ad35 (1 g/ml).
3 H-labeled Ads were then added at an MOI of 8,000 VP per cell, and attachment was analyzed.
b An antibody (Ab) competition assay was carried out as described for the same receptor, which is different from CD46. Group III Ad11 uses both CD46 and receptor X and can block binding of group I and II Ads. Ad11p appears to have a higher affinity toward CD46 than toward receptor X, as Ad11p only binds to receptor X when CD46 is blocked. Group I Ads use CD46. Binding of Ad35knob/virus to CD46 appears to affect interaction of Ad3, -7p, and -14 with receptor X. Along this line, CD46 antibodies specific to the Ad35 binding domain of CD46 partially inhibit Ad3 binding (Table 4 , lower section), suggesting a potential physical juxtaposition of the two receptors.
Receptor number and affinity. Binding studies in combination with Scatchard blot analyses were performed to measure the affinity (K a ) of Ads for receptor X and receptor numbers on two representative cell cultures, K562 cells and MES cells. MES cells that efficiently bind Ad3 were used as target cells (Fig. 4) . To assess the impact of CD46 on K a , binding studies were performed in the presence and absence of the MEM-258 MAb. On MES cells, more Ad3 binding sites (72,220) than Ad35 binding sites (28, 822) were found. While the K a of Ad3 did not change in the presence of the MEM-258 MAb, the K a for Ad35 binding decreased by more than 1 order of magnitude, indicating that Ad35 is unlikely to bind with sufficient affinity to a cellular receptor other than CD46. The affinity of Ad3 toward receptor X was lower than the affinity of Ad35 toward CD46. The outcome of studies with K562 cells was similar, although the numbers of both Ad3 and Ad35 receptors were higher than on MES cells (85,040 and 54,589, respectively). This study and Fig. 3D also support our earlier observation that Ad11p has a higher affinity toward CD46 than toward receptor X. MEM-258 reduced the K a of A11p to a higher degree than the K a of Ad3, suggesting that Ad3 has a higher affinity for receptor X than Ad11p does. Taken together, this indicates that, on both MES and K562 cells, receptor X is more abundantly expressed but has less Ad binding affinity than CD46 does.
Characterization of receptor X. We next attempted to better characterize receptor X, which is used by group II and III Ads. Attachment studies were performed with group I Ad3 and HeLa cells after pretreatment of cells with trypsin (Fig. 5A) . Trypsin pretreatment inhibited Ad3 binding, suggesting that receptor X is a protein. In contrast, trypsin pretreatment enhanced Ad35 binding to CD46, which can be blocked by the MEM-258 MAb. This indicates that the Ad35 binding domain(s) of CD46 is relatively resistant to trypsin. We also speculate that removal of other cell surface proteins opens access to CD46 or reduces electrostatic repulsion between Ad35 and CD46. Furthermore, pretreatment of cells with tunicamycin at a concentration that effectively inhibits N-glycosylation of CD46 (8) significantly reduced binding of Ad3 to HeLa cells, suggesting that carbohydrate side chains might be involved in Ad3 interaction with receptor X (Fig. 5B) . (In agreement with earlier observations, N-glycosylation of CD46 is not critical for Ad35 binding [8] .) Binding of Ad3 was almost entirely dependent on divalent cations, while EDTA and EGTA pretreatment had no effect on Ad35 binding (Fig. 5C) . Importantly, none of the antibodies against other CD46 domains (CCP1, -3, and -4) blocked Ad3 binding more than the CCP2-specific antibody (Fig. 5D) . Furthermore, preincubation of HeLa cells with the complement factor C3b, at a concentration that inhibited binding of an anti-CCP3/4 antibody, did not decrease attachment of Ad3 (data not shown). Taking these finding together, it is highly unlikely that other domains of CD46 are involved in Ad3 binding. To ultimately show that Ad3 does not use CD46, we transfected HeLa cells with CD46 siRNA to knock down CD46 expression (7) . Figure 5E shows that in CD46 siRNA-transfected cells but not in cells treated with control siRNA, Ad35 binding decreased 77.8% while Ad3 binding increased 1.1%. This finding also provides further evidence that the reduction of Ad3 binding by the MEM-258 MAb and Ad35/Ad35 knob is unspecific and probably due to steric hindrance.
To analyze the presence of group B Ad receptors in different species, we infected CD34 ϩ cells with Ad5/11 and Ad5/35, which express the gene for GFP under the control of the murine stem cell virus or CMV promoter. Interestingly, Ad5/11 vectors cannot transduce CD34 ϩ cells from dogs and mice (Fig. 5F ), which argues against the presence of receptor X in these species. In contrast, CD34 ϩ cells from primates (humans, macaques, and baboons) are efficiently transduced by Ad5/35 or Ad5/11 vectors, indicating that both group B Ad receptors, CD46 and receptor X, are well conserved within different species of primates.
A number of lines of data suggest that receptor X is an integrin. (i) Cations (Ca 2ϩ ) are important in maintaining the structure of integrins (11), (ii) integrins are expressed at a high density on the surface of most cells including stem cells (4), (iii) integrins form complexes with CD46 (20) , and (iv) integrins are functionally involved in tumor invasion and metastasis and are therefore upregulated during tumor progression (10) . To assess whether receptor X is an integrin, we analyzed surface expression of the most common integrins on HeLa and K562 cells, cell lines that both efficiently bind Ad3 ( Table 1 ). Integrins that are significantly expressed at high levels on both cell lines include ␣5, ␣v, ␤1, and ␣v␤5 (Fig. 6A) . In further studies, we therefore focused on those integrins. Other cell lines (293, MHF2, and SKOV3) that bind Ad3 also showed significant integrin ␣v, ␤1, and ␣v␤5 expression, whereas integrin ␣5 was less detectable in 293 cells. Of interest, Y79 cells, a CD46
high cell line that expresses no or only very low levels of integrins (38) , does not efficiently bind Ad3 (Fig. 6B) . Despite indications that ␣v, ␤1, and ␤5 are candidates for receptor X, we were not able to confirm a critical role for these integrins in Ad3 binding. Antibodies against the most widely expressed ␣ and ␤ integrin subunits, including ␣v, ␤1, and ␤5, did not significantly block Ad3 binding to HeLa cells (Fig. 6C) . Previous studies showed that these antibodies block Ad5 vector uptake and infection at the concentration used in our competition experiments (19) . More importantly, knockdown of critical integrin subunit ␤1 and ␣v expression by siRNA did not affect Ad3 binding (Fig. 6D) . (In the present study, siRNA transfection resulted in a Ͼ25% decrease in ␤1 and ␣v integrin levels on the surface of HeLa cells, as determined by flow cytometry.) Notably, integrins can only be displayed at the cell surface as ␣␤ heterodimers and knockdown of one the subunits prevents presentation of the corresponding integrin (11) . Finally, ectopic expression of ␣v and ␤1 integrins in CHO cells did not increase Ad3 binding compared to that in naive CHO cells (data not shown).
In conclusion, our data indicate that receptor X is an abundantly expressed glycoprotein that interacts with group II and III Ads at relatively low affinity in a bivalent-cation-dependent manner. Our finding that this receptor is apparently expressed at high levels and with uniformity on stem cells and tumor cell lines has practical implications for gene therapy.
DISCUSSION
A classification of group B Ad receptors was previously introduced by Segerman et al. in 2003 (31) . They suggested that all group Ads interact with a common receptor (species B Ad receptor). In addition, species B2 Ads (Ad11, -14, -34, -35, and -50) were thought to interact with an additional receptor, designated the species B2 Ad receptor, which is identical to CD46. We propose a revised classification of group B Ads on the basis of the usage of attachment receptors. Our classification is not in agreement with the subdivision into species B1 and B2 Ads (which focuses on genetic differences). Group I Ads (Fig. 1A) . Finally, incubation of Ad11p and Ad35 with soluble CD46 inhibited their binding to HeLa cells and MES cells (Table 4) , whereas Ad3, -7p, and -14 binding levels were not significantly affected. These observations support our conclusion that receptor X is different from CD46.
The finding that the MEM-258 MAb partially inhibits the binding of Ad3, -7, and -14 to several CD46 high cell lines suggests that the cellular receptor for Ad3 is in close physical proximity to CD46 rather than being CD46 itself. Interestingly, this effect is not as pronounced on primary cells, which have lower CD46 densities. Inhibition of Ad3 binding by CD46 antibodies could be simply due to a high density of receptor X and CD46 on the cell surface. On the other hand, this could indicate that these molecules are coreceptors, implying that binding to one receptor transfers Ad to the other receptor, which, for example, might mediate endocytosis. This is a strategy used by other viruses, including human immunodeficiency virus and reovirus (2) . However, our finding that efficient infection of Ad3, -7p, -11p, and -14 occurs via receptor X in the presence of the MEM-258 MAb, as well as the CD46 knockdown and soluble CD46 blocking data, argues against such a coreceptor relationship. The nature of Ad3 blocking by CD46 antibodies remains to be investigated.
The identification of receptor X has important implications for adenovirology and gene therapy. Early studies showed that the Ad3 fiber interacted with a 130-kDa protein in a divalentcation-dependent manner, while a recent study suggested that CD80 (B7-1) and CD86 (B7-2) function as cellular attachment receptors for Ad3 (36) . However, because CD80 and CD86 are mainly expressed on antigen-presenting cells and not on HeLa or MES cells (data not shown), it is unlikely that these two molecules represent receptor X. We found that receptor X is an abundantly expressed protein that is apparently primate specific. The K a for binding to receptor X is less than that for binding to CD46. This might be due in part to protein-carbohydrate interactions, which are typically of a weak nature. Our finding that chelation of divalent cations had a negative effect on Ad3 binding but not Ad35 binding is in agreement with earlier studies (32) . Although a series of data were indicative of a role for integrins in Ad group II and III binding, blocking studies with integrin-specific antibodies and siRNA did not support this indication. Furthermore, despite the fact that quiescent CD34 ϩ cells express very small amounts of ␣v integrins, Ad3 binding to and infection of hematopoietic cells were efficient (23) . While receptor X appears to be expressed on hematopoietic cells, it seem to be lost upon differentiation as Ad3 does not efficiently bind anymore to peripheral blood mononuclear cells (33) or DC (see Table 2 ). Notably, ␣5, ␣v, and ␤1 integrins are expressed at high levels on DC (14, 29) . Taken together, these findings appear to argue against integrins as a candidate for receptor X. We are currently performing more systematic studies with recombinant Ad3 and Ad11 fiber knob domains to purify virus-interacting proteins from MES cell membrane lysates, essentially as we have done before for the identification of CD46 (7) . In this study, we showed that receptor X is expressed at high levels on MES cells and undifferentiated ES cells, derived from line hSF6, and that an Ad11 fiber-containing Ad vector efficiently transduced these cells when CD46 was blocked. This is, to our knowledge, the first study that demonstrates efficient transduction of undifferentiated human ES cells by Ad vectors. In transduction studies, we also found that the CMV promoter, in the context of a first-generation Ad5/35 or Ad5/11 vector, is not active in undifferentiated cells, which is in conflict with a recent study by Kim et al. that found efficient CMV promoterdriven transgene expression in ES cells after plasmid transfection (16) . Notably, these authors did not confirm the undifferentiated stage of ES cells. We also demonstrated that an RSV promoter can confer efficient transgene expression in ES cells after infection with Ad5/35 or Ad5/11 vectors at low MOIs.
Furthermore, our binding studies show that Ad3, -7p, -14, and -11p bind more efficiently to cancer cell lines than to primary human fibroblasts or DC, which indicates that receptor X is expressed at higher levels on tumor cell lines than on normal tissue. Our data are supported by a recent study showing that a chimeric virus that utilizes the Ad3 fiber (Ad5/3) preferentially and efficiently infects primary ovarian cancer cells in vitro (15) . Of particular interest is also that Ad11 can use two receptors (CD46 and receptor X) present at high levels on tumor cells, which potentially reduces the risk of development of escape mutants by downregulation of Ad attachment receptors in gene therapy trials with oncolytic Ads. Furthermore, Ad11 fiber interaction with receptor X does not increase transduction of normal tissue, as vector biodistribution in baboons after intravenous injection of Ad5/35 and Ad5/11 is similar (25) .
In conclusion, our studies indicate that a subset of group B Ads bind to important gene therapy targets independent of CD46. This finding is important for both understanding the molecular mechanisms of Ad pathogenicity and developing group B Ads as a tool for gene therapy.
